Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
2024 · Infectious Diseases and Therapy · 6 citations
https://doi.org/10.1007/s40121-024-00961-y